The group’s principle activity is to utilize novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The group’s product pipeline includes products for chronic and progressive disorders. The group also provides research and development services on diseases characterized by undesirable immune responses. The group operates from United States.
